Filing Details
- Accession Number:
- 0001628280-24-026851
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-05 16:23:25
- Reporting Period:
- 2024-06-03
- Accepted Time:
- 2024-06-05 16:23:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1104506 | Insmed Inc | INSM | Pharmaceutical Preparations (2834) | 541972729 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1401017 | Nicole S Orlov Schaeffer | 700 Us 202/206 Bridgewater NJ 08807 | Chief People Strategy Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-03 | 13,750 | $16.07 | 122,510 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-06-03 | 41,250 | $22.76 | 163,760 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-06-03 | 55,000 | $55.33 | 108,760 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-06-03 | 13,750 | $0.00 | 13,750 | $16.07 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-06-03 | 41,250 | $0.00 | 41,250 | $22.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-01-08 | No | 4 | M | Direct | |
| 0 | 2025-05-21 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- This is the weighted average sales price representing 55,000 shares sold at prices ranging from $54.69 to $55.65 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
Billionaire Hedge Funds
